-
α-Bungarotoxin: Blocking Receptors, Testing Translation
2026-09-04
α-Bungarotoxin is more than a receptor antagonist: it is a causal pharmacology tool for testing whether α7 nicotinic acetylcholine receptor signaling connects cholinergic activity with tissue injury, inflammation, and necroptosis. This article translates recent placental findings into practical guidance for neuroscience and translational research workflows.
-
WZ4003: Translating NUAK Biology Across Models
2026-09-03
WZ4003 is a selective NUAK1/2 inhibitor that connects kinase mechanism with actionable workflows in cancer research and neurodegeneration. This thought-leadership guide examines target engagement, model selection, assay strategy, translational limitations, and the emerging relevance of NUAK1-dependent tau phosphorylation.
-
DAPT (GSI-IX) in Corneal Epithelial Cell Assays
2026-09-03
DAPT (GSI-IX) helps researchers separate γ-secretase-dependent effects on cell fate, epithelial maintenance, APP processing, and Notch activity. Its strongest use-case is a controlled pathway perturbation embedded in well-designed cell models, including the feeder-free corneal culture paradigm described in the reference study.
-
Selective Autophagy Tunes IRF3 Stability and IFN
2026-09-02
Wu and colleagues show that CALCOCO2/NDP52-dependent selective autophagy regulates IRF3 abundance according to viral burden, while PSMD14 preserves IRF3 through deubiquitination. The findings connect ubiquitin editing, lysosomal turnover, and type I interferon output in a mechanism that helps balance antiviral defense with immune suppression.
-
Oseltamivir acid: An Assay-First Research Guide
2026-09-02
Oseltamivir acid is an influenza neuraminidase inhibitor with value beyond routine antiviral screening. This assay-first guide connects mechanism, resistance testing, formulation, oncology models, and human-relevant pharmacokinetic study design.
-
DMH1 Workflows for ALK2 Inhibition in Organoids
2026-09-01
DMH1 provides a practical way to interrogate ALK2-driven BMP signaling in tunable intestinal organoids and NSCLC cell assays. This guide connects pathway-selective inhibition with reproducible dosing, phospho-Smad validation, organoid fate analysis, and lung cancer migration workflows.
-
EZ Cap™ Firefly Luciferase mRNA: Assay Design
2026-09-01
EZ Cap™ Firefly Luciferase mRNA enables sensitive, cap-optimized protein expression for reporter studies. This article explains how to interpret luminescence as a composite readout shaped by delivery, translation, redox state, and cell physiology.
-
Paroxetine Mesylate: From SSRI to Cancer Assay
2026-08-31
Paroxetine Mesylate is a Selective serotonin reuptake inhibitor with a pharmacology that extends beyond SERT. This article translates its MET–ERBB3 colorectal cancer evidence into a practical, evidence-aware assay strategy while distinguishing mechanistic hypotheses from validated findings.
-
Palmitic acid: Protocol and QC Guide
2026-08-31
Palmitic acid (hexadecanoic acid, SKU N2456) provides a defined saturated long-chain fatty acid input for studies of lipid metabolism, insulin signaling, inflammation, and protein palmitoylation. It is unsuitable for aqueous-only protocols and should be prepared in a compatible organic solvent, used promptly, and stored as a sealed solid at -20°C.
-
MHY1485: A Mechanistic mTOR–Autophagy Guide
2026-08-30
MHY1485 is an mTOR activator that also disrupts autophagosome–lysosome fusion. This mechanism-first guide connects pathway biology from an EBV–NPC study to rigorous autophagy assay design, translational interpretation, and ovarian follicle development research.
-
PPARγ Activation in DSS-Induced IBD
2026-08-29
The reference study shows that pioglitazone-mediated PPARγ activation reduces DSS-induced intestinal inflammation by shifting macrophage polarization away from an M1-dominant state and toward an M2-associated profile. Its combined cell and mouse experiments connect these changes to opposing effects on STAT-1 and STAT-6 phosphorylation, providing a useful framework for studying inflammatory process modulation.
-
Cediranib (AZD2171): Beyond Viability
2026-08-28
Cediranib (AZD2171) is an angiogenesis inhibitor whose pathway effects can be obscured by conventional viability assays. This guide integrates VEGFR biology with a two-axis framework for separating growth inhibition from cell killing in cancer research.
-
KX2-391 Dihydrochloride: Assay Workflows
2026-08-28
KX2-391 dihydrochloride supports integrated oncology, HBV, and BoNT/A workflows by combining substrate-site Src inhibition with disruption of tubulin polymerization. This guide translates reported potency ranges into practical assay setup, controls, troubleshooting steps, and mechanism-aware interpretation.
-
JNJ-26481585: An Assay Strategy for HDAC Biology
2026-08-27
JNJ-26481585 (Quisinostat) is a potent epigenetic modulator for connecting HDAC inhibition with apoptosis, proliferation, and drug resistance. This guide translates recent TRIM21–ERK1/2 findings into a rigorous, multi-readout assay strategy rather than treating viability as a standalone endpoint.
-
Olsalazine Sodium: Research Workflows
2026-08-27
Olsalazine Sodium connects LTB4-driven inflammation assays with colorectal cancer tumor models and emerging mosquito xenobiotic-transport workflows. This practical guide covers aqueous formulation, dose selection, paired molecular and physiological readouts, and troubleshooting for reproducible experiments.